PMID- 24922671
OWN - NLM
STAT- MEDLINE
DCOM- 20140821
LR  - 20201219
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 34
IP  - 6
DP  - 2014 Jun
TI  - Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for 
      patients with metastatic colorectal cancer.
PG  - 3045-52
AB  - AIM: The combination of a peptide vaccine and tegafur-uracil plus leucovorin 
      (UFT/LV) were evaluated in patients with metastatic colorectal cancer refractory 
      to standard chemotherapy. PATIENTS AND METHODS: Thirty human leukocyte antigen 
      (HLA)-A2402-positive patients were enrolled in the study. In a cycle of 
      treatment, a vaccine comprising of seven synthetic peptides (five tumor 
      antigen-derived and two vascular endothelial growth factor receptor-derived) was 
      injected weekly, and oral chemotherapy, UFT/LV was given daily for four weeks 
      followed by one week of rest. The immunological and clinical responses were 
      evaluated at the end of every five weeks. RESULTS: Notable adverse events 
      included grade 1 injection site redness/induration in 25 patients. Tumor imaging 
      showed partial response in three patients, stable disease in 15, and progressive 
      disease in 12. Survival analysis indicated that patients who exhibited positive 
      cytotoxic T lymphocyte responses to all seven peptides had longer overall 
      survival compared to other patients. CONCLUSION: A 7-peptide vaccine used with 
      UFT/LV is safe and is recommended for further trials in patients with metastatic 
      colorectal cancer.
CI  - Copyright(c) 2014 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Okuno, Kiyotaka
AU  - Okuno K
AD  - Department of Surgery, Kinki University Faculty of Medicine, Osaka-sayama, Osaka, 
      Japan okuno@surg.med.kindai.ac.jp.
FAU - Sugiura, Fumiaki
AU  - Sugiura F
AD  - Department of Surgery, Kinki University Faculty of Medicine, Osaka-sayama, Osaka, 
      Japan.
FAU - Inoue, Keisuke
AU  - Inoue K
AD  - Department of Surgery, Kinki University Faculty of Medicine, Osaka-sayama, Osaka, 
      Japan.
FAU - Sukegawa, Yasushi
AU  - Sukegawa Y
AD  - Institute of Immunotherapy for Cancer, Kinki University Faculty of Medicine, 
      Osaka-sayama, Osaka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*immunology
MH  - Cancer Vaccines/*therapeutic use
MH  - Colorectal Neoplasms/mortality/secondary/*therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Survival Rate
MH  - Vaccines, Subunit/*therapeutic use
OTO - NOTNLM
OT  - 7-peptide vaccine
OT  - Cancer vaccine
OT  - clinical trial
OT  - metastatic colorectal cancer
OT  - oral chemotherapy
OT  - refractory to standard chemotherapy
EDAT- 2014/06/13 06:00
MHDA- 2014/08/22 06:00
CRDT- 2014/06/13 06:00
PHST- 2014/06/13 06:00 [entrez]
PHST- 2014/06/13 06:00 [pubmed]
PHST- 2014/08/22 06:00 [medline]
AID - 34/6/3045 [pii]
PST - ppublish
SO  - Anticancer Res. 2014 Jun;34(6):3045-52.